Patents Issued in March 12, 2024
  • Patent number: 11926638
    Abstract: Provided are compounds having a tetradentate structure of that are useful as emitters in OLED applications.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: March 12, 2024
    Assignee: UNIVERSAL DISPLAY CORPORATION
    Inventors: Hsiao-Fan Chen, Jason Brooks, Chun Lin, Hai T. Le, Steven Kit Chow, Neetipalli Thrimurtulu
  • Patent number: 11926639
    Abstract: A process for preparing oligo ethylene glycol methyl ether borate involves feeding boric acid and oligo ethylene glycol monomethyl ether into a reactor, and reacting to obtain a raw product containing oligo ethylene glycol methyl ether borate, water, and unreacted boric acid and oligo ethylene glycol monomethyl ether. The raw product is fed to a reactive distillation device and boric acid is reacted with oligo ethylene glycmonomethyl ether for full conversion of boric acid. A distillate stream containing water is transferred from the top of the reactive distillation device to a condenser, and a condensed liquid stream is recycled to the top of the reactive distillation device. A bottom product stream containing oligo ethylene glycol methyl ether borate is withdrawn from the reactive distillation device. The bottom product stream is partially recycled to a reboiler. The resulting vapor stream is recycled to the bottom of the reactive distillation device.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: March 12, 2024
    Assignee: BASF SE
    Inventors: Kathrin Luise Mariethres Werth, Thomas Holtmann, Rainer Papp, Mirko Haider, Joachim Wulff-Doering
  • Patent number: 11926640
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: March 12, 2024
    Assignees: The Johns Hopkins University, Ústav organické chemie a biochemie AV {hacek over (C)}R, v.v.i.
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
  • Patent number: 11926641
    Abstract: The invention provides a compound of formula I: or a salt thereof, wherein R1-R4 have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful in immunotherapy as a potential treatment, or co-treatment, for cancer or infectious diseases.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: March 12, 2024
    Assignee: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: David F. Wiemer, Andrew J. Wiemer
  • Patent number: 11926642
    Abstract: The invention relates to compounds of formula I wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: March 12, 2024
    Assignee: Pfizer inc.
    Inventors: Robert Steven Kania, Padmavani Bezawada, Emma Louise Hawking, Rohit Jaini, Samir Kulkarni, Matthew Nathan O'Brien Laramy, Jonathan Richard Lillis, Suman Luthra, Dafydd Rhys Owen, Klimentina Dimitrova Pencheva, Anil Mahadeo Rane, Matthew Forrest Sammons, Bradley Paul Sullivan, Andrew John Thiel, Martyn David Ticehurst, Jamison Bryce Tuttle, Robert Louis Hoffman
  • Patent number: 11926643
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: March 12, 2024
    Assignee: Gasherbrum Bio, Inc.
    Inventors: Qinghua Meng, Xichen Lin, Haizhen Zhang, Weiqiang Xing, Hui Lei, Andrew Jennings
  • Patent number: 11926644
    Abstract: Disclosed is a compound of formula (I): wherein R1, R2, R3, and are as defined herein. Also disclosed are methods for increasing mammalian cell NAD+ production and improving mitochondrial cell densities comprising administering to a cell the compound or a salt thereof.
    Type: Grant
    Filed: July 27, 2021
    Date of Patent: March 12, 2024
    Assignee: Cornell University
    Inventors: Anthony Sauve, Farheen Sultana Mohammed, Yue Yang
  • Patent number: 11926645
    Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and salts, crystalline forms, pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: March 12, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Elaine Bunyan, Byoung-Kwon Chun, Kassibla E. Dempah, Hon C. Hui, Rao V. Kalla, Richard L. Mackman
  • Patent number: 11926646
    Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1B, n, R2A, R2B, R3, and R4 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: March 12, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Andrew Griffin, Boyd L. Harrison, Daniel La
  • Patent number: 11926647
    Abstract: The invention encompasses components from microbial cells which are useful for antibody production, including peptides, polypeptides comprising these peptides, polynucleotides which encode these peptides or polypeptides, and antibodies directed to these peptides, polypeptides, or polynucleotides. The invention also encompasses to expression vectors and host cells for producing these peptides, polypeptides, polynucleotides, and antibodies. The invention further encompasses methods and compositions, especially vaccine compositions, for detecting, targeting, and inhibiting microbial cells, especially methanogen cells, using one or more of the disclosed peptides, polypeptides, polynucleotides, antibodies, expression vectors, and host cells.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: March 12, 2024
    Assignee: Pastoral Greenhouse Gas Research Limited
    Inventors: Eric Heinz Altermann, Graeme Trevor Attwood, Dong Li, William John Kelly, Zhanhao Kong, Sinead Christine Leahy
  • Patent number: 11926648
    Abstract: A flavivirus Envelope Dimer Epitope (EDE) and isolated neutralizing antibody or antigen binding fragment thereof directed against the EDE for use in vaccinating an individual against one or more flaviviruses wherein the EDE is a stabilized recombinant flavivirus are provided. The dimer is: covalently stabilized with at least one disulphide inter-chain bond or one sulfhydryl-reactive crosslinker between the two sE monomers, and/or by being formed as a single polypeptide chain, and/or by linking the two sE monomers through modified sugar, and/or non-covalently stabilized by substituting at least one amino acid residue in the amino acid sequence of at least one sE monomer with at least one bulky side chain amino acid, at the dimer interface or in domain 1 (D1)/domain 3 (D3) linker of each monomer. The dimer is a homodimer or heterodimer of native and/or mutant envelope polypeptides, from DENV-1, DENV-2, DENV-3, DENV-4, Zika and/or other flavivirus.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: March 12, 2024
    Assignees: INSTITUT PASTEUR, IMPERIAL COLLEGE INNOVATIONS LIMITED
    Inventors: Felix Rey, Giovanna Barba Spaeth, Marie-Christine Vaney, Alexander Rouvinski, Gavin Screaton, Juthathip Mongkolsapaya
  • Patent number: 11926649
    Abstract: The present invention provides mutant RSV F molecules, such as those that can be, or are stabilized, in a pre-fusion conformation by the introduction of one or more DT cross-links. The present invention also provides methods of making such mutant RSV F molecules, compositions comprising such mutant RSV F molecules, and methods of use of such mutant RSV F molecules, for example in vaccination methods, therapeutic methods, and antibody production methods.
    Type: Grant
    Filed: February 9, 2022
    Date of Patent: March 12, 2024
    Inventors: Christopher Marshall, Mark Yondola, Roberto Mariani, Aaron Zomback, Sonal Gidwani
  • Patent number: 11926650
    Abstract: The present invention relates to a method for processing fresh algae at ambient temperature by subjecting algae to an osmotic shock and treating the disrupted algae with an enzyme composition comprising cell wall degrading enzymes. This gentle process at ambient temperature allows for the isolation of algal protein which has good solubility, also in the presence of salt and good foaming, emulsifying and water binding properties. Another advantage is that this method of protein isolation allows for cascaded biorefinery, since protein isolation may be followed by a treatment of the remaining biomass with carbohydrate degrading enzymes to produce clean biogas in high yields and a mineral rich water stream in anaerobic digestion.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: March 12, 2024
    Assignee: SABIDOS B.V.
    Inventor: Theodorus Verleun
  • Patent number: 11926651
    Abstract: The present invention relates to a polypeptide construct comprising at least two fragments of an allergen from the Amb a 1 family of allergens from Ambrosia atermisiifolia or variants of said at least two fragments, wherein each of the at least two fragments consist of 20 to 50 amino acid residues and wherein at least one fragment is derived from amino acid residues 1 to 50 of the mature allergen and at least one fragment is derived from amino acid residues 240 and ending at the C-terminal end of the mature allergen.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: March 12, 2024
    Assignee: WORG PHARMACEUTICALS (ZHEJIANG) CO., LTD.
    Inventors: Monika Hochradl, Frank Stolz, Angela Neubauer, Rainer Henning, Elijahu Babaev
  • Patent number: 11926652
    Abstract: Provided herein are recombinant CTLA-4 binding proteins, which are, inter alia, useful for the treatment of cancer. The recombinant proteins provided herein are, inter alia, capable of binding CTLA-4 proteins on a tumor cell. In a first aspect, there is provided a recombinant CTLA-4 binding protein including (i) a CTLA-4 binding domain; (ii) a CTLA-4 binding domain masking peptide; and (iii) a cleavable peptide linker connecting the CTLA-4 binding domain masking peptide to the CTLA-4 binding domain. In another aspect, there is provided a dimerizing domain covalently attached to the CTLA-4 binding domain, wherein the binding protein domains are bound together.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: March 12, 2024
    Assignees: City of Hope, Thomas Jefferson University and Health System, Innovation Pillar
    Inventors: John Williams, Ulrich Rodeck, Miso Park, Kurt Jenkins
  • Patent number: 11926653
    Abstract: The present disclosure relates to recombinant adeno-associated vims (rAAV) delivery of a neurotrophin 3 (NT-3) polynucleotide. The disclosure provides rAAV and methods of using the rAAV for NT-3 gene therapy to improve muscle strength, stimulate muscle growth and to treat muscle wasting disorders, such as muscular dystrophy and Charcot-Marie-Tooth neuropathy.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: March 12, 2024
    Assignee: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
    Inventor: Zarife Sahenk
  • Patent number: 11926654
    Abstract: The present invention describes fusion proteins based on cytokines, called bi-cytokines (BC), specifically formed by the binding of an IL2 agonist mutein with a type I interferon (IFN), linked by an Fc region of a mutant human IgG1 and a connector peptide. The combination of an IL2 agonist mutein and a type I IFN in the structure of the bi-cytokines gives surprising immunoregulatory properties to these molecules and a superior therapeutic effect than that of parental cytokines, or their combination, which makes them attractive and novel molecules for the treatment of cancer. Pharmaceutical compositions comprising as an active ingredient the fusion proteins object of this patent are also described.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: March 12, 2024
    Assignee: CENTRO DE INMUNOLOGIA MOLECULAR
    Inventors: Tays Hernández García, Maura Lisett Rábade Chediak, Kalet León Monzón, Circe Mesa Pardillo, Luis Enrique Fernández Molina, Giselle Hevia Hernández
  • Patent number: 11926655
    Abstract: The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: March 12, 2024
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Hidenori Yano, Daisuke Nishimiya, Ryuji Hashimoto, Yoichi Niitsu
  • Patent number: 11926656
    Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus (EBV) infection in mammals, and methods of using those compositions of matter for the detection, diagnosis and treatment of EBV infection are described. Also described are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: March 12, 2024
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Wei Bu, Masaru Kanekiyo, Michael Gordon Joyce, Jeffrey I. Cohen
  • Patent number: 11926657
    Abstract: Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza A virus and a second binding domain that specifically binds influenza B virus.
    Type: Grant
    Filed: November 11, 2022
    Date of Patent: March 12, 2024
    Assignee: MEDIMMUNE, LLC
    Inventors: Nicole Kallewaard-Lelay, Qing Zhu, Godfrey Jonah Rainey, Cuihua Gao, Srinath Kasturirangan, Changshou Gao
  • Patent number: 11926658
    Abstract: The invention relates to multispecific antibodies, and antigen binding fragments thereof, that specifically bind to distinct Zika virus epitopes and potently neutralize infection of ZIKV. The invention also relates to nucleic acids that encode such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in prophylaxis and treatment of ZIKV infection.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: March 12, 2024
    Assignee: HUMABS BIOMED SA
    Inventor: Davide Corti
  • Patent number: 11926659
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: March 12, 2024
    Assignee: Prothena Biosciences Limited
    Inventors: Tarlochan S. Nijjar, Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • Patent number: 11926660
    Abstract: The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of Aß plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.
    Type: Grant
    Filed: August 24, 2021
    Date of Patent: March 12, 2024
    Assignee: Washington University
    Inventors: David Holtzman, Hong Jiang, Thu Nga Bien-Ly, Mark S. Dennis, Jing Guo, Adam P. Silverman, Ryan J. Watts, Yin Zhang
  • Patent number: 11926661
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind to human artemin. Methods for using anti-artemin antibodies and antigen-binding fragments are also provided.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: March 12, 2024
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Susan D. Croll, Lynn MacDonald, Andrew J. Murphy
  • Patent number: 11926662
    Abstract: Provided are anti-GM-CSF antibodies or fragments thereof including humanized antibodies and fragments. Also provided are uses of the antibodies and fragments for therapeutic, diagnostic and prognostic purposes. Therapeutic uses of the antibodies and fragments, for example include the treatment of inflammatory and autoimmune diseases and disorders.
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: March 12, 2024
    Assignee: I-Mab Biopharma (Hangzhou) Co., Ltd.
    Inventors: Zhengyi Wang, Lei Fang, Bingshi Guo, Jingwu Zang
  • Patent number: 11926663
    Abstract: The present invention provides means and methods for treating Interleukin 18 (IL-18)-associated diseases and disorders. In particular, the present invention discloses antibodies specific for free IL-18 and IL-18 Binding Protein (IL-18BP) for use in such treatments and for the diagnosis of the diseases and disorders.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: March 12, 2024
    Assignee: AB2 BIO SA
    Inventors: Greg Del Val, Eduardo Schiffrin
  • Patent number: 11926664
    Abstract: Monocytopoiesis is a hematological process that supplies the periphery with monocytes and subsequently with macrophages and monocyte-derived dendritic cells. Typically, monocytes circulate in the bloodstream for a very short time before undergoing apoptosis, however, stimulatory signals can trigger monocyte survival by inhibiting the apoptotic pathway, and thus contribute to the maintenance of the inflammatory response. Accordingly, there is a need for methods and pharmaceutical compositions for modulating monocytopoiesis. Now, the inventors show that type I interferons signaling promote the differentiation of monocyte-derived phagocytes at the level of their progenitors. Importantly, IFN-alpha and -beta were found to efficiently generate the development of monocyte-derived antigen-presenting cells while having no impact on the precursor activity of conventional dendritic cells. Accordingly, modulators of type I interferon (e.g.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: March 12, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ DE LILLE
    Inventors: Lionel Poulin, Corentin Lasseaux, Mathias Chamaillard
  • Patent number: 11926665
    Abstract: The present disclosure provides methods of administering certain TIM-3 binding agents to patients having cancer. Dosage regimens for compositions comprising a TIM-3 binding agent are also explicitly provided.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: March 12, 2024
    Assignee: TESARO, INC.
    Inventors: Dmitri Bobilev, Andrew R. Ferguson, Kristen Anne McEachern, Jing Wang
  • Patent number: 11926666
    Abstract: The present invention relates to a bispecific antibody construct comprising a first human binding domain which binds to human CDH3 on the surface of a target cell and a second binding domain which binds to human CDS on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: March 12, 2024
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Bertram Weiss, Anna-Lena Frisk, Ruprecht Zierz, Peter Kufer, Tobias Raum, Doris Rau, Jonas Anlahr, Ralf Lutterbüse, Lisa Nahrwold, Christoph Dahlhoff, Claudia Blümel, Patrick Hoffmann
  • Patent number: 11926667
    Abstract: Provided herein, in certain aspects, are antibodies that bind to CD8, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are antibodies that bind to CD4, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are multispecific antibodies that bind to CD4 and CD8, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making the antibodies are also provided.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: March 12, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Rajkumar Ganesan, Sanjaya Singh, Iqbal S. Grewal, Michael Riis Hansen
  • Patent number: 11926668
    Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., lung cancer). The methods of the present invention comprise administering a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody), to a subject with lung cancer wherein the cancer tissue expresses PD-L1.
    Type: Grant
    Filed: February 28, 2022
    Date of Patent: March 12, 2024
    Assignee: Regeneron Pharmaceuticals Inc.
    Inventors: Petra Rietschel, Israel Lowy
  • Patent number: 11926669
    Abstract: The present disclosure relates to an anti-FcRn antibody or an antigen binding fragment thereof with improved stability and uses thereof. The anti-FcRn antibody or antigen binding fragment thereof binds to FcRn non-competitively with IgG and the like compared to the parent antibody, HL161AN, thereby having improved stability, such as reducing the production rate of aggregates while maintaining the biological activity of significantly reducing the amount of pathogenic autoantibodies in the blood. Therefore, it may be utilized more efficiently for the treatment of an autoimmune disease.
    Type: Grant
    Filed: June 23, 2023
    Date of Patent: March 12, 2024
    Assignees: HANALL BIOPHARMA CO., LTD., IMMUNOVANT SCIENCES GMBH
    Inventors: William Louis Macias, Su Liang, Hyeakyung Ahn, Haeyoung Yong, Mijin Jung, Minho Yoon, Eunsun Kim, Seungkook Park, Hyeeun Shim
  • Patent number: 11926670
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: March 12, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Xiaolin Tang
  • Patent number: 11926671
    Abstract: The invention is in the field of antibodies useful in therapeutic and diagnostics applications targeting CD127, the alpha chain of the IL7 receptor, and provides in particular humanized monoclonal antibodies against CD127, particularly human CD127, therapeutic uses thereof, and diagnostics applications.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: March 12, 2024
    Assignee: OSE IMMUNOTHERAPEUTICS
    Inventors: Nicolas Poirier, Caroline Mary, Bernard Vanhove, Virginie Thepenier
  • Patent number: 11926672
    Abstract: The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: March 12, 2024
    Assignee: Amgen Inc.
    Inventors: Xin Yu, Jackson Egen, Fernando Garces, Shunsuke Takenaka, AeRyon Kim, Deepali Sawant
  • Patent number: 11926673
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Grant
    Filed: January 19, 2022
    Date of Patent: March 12, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
  • Patent number: 11926674
    Abstract: The invention provides anti-Jagged2 antibodies and methods of using the same.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: March 12, 2024
    Assignee: Genentech, Inc.
    Inventors: Yvonne Chinn, Julie Q. Hang, Christian W. Siebel, Yan Wu, Daniel Lafkas
  • Patent number: 11926675
    Abstract: Disclosed is an antibody that specifically binds CD24, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD24 signaling using the antibody or antigen binding portion thereof are also provided.
    Type: Grant
    Filed: March 3, 2022
    Date of Patent: March 12, 2024
    Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
    Inventors: Wenzhi Tian, Song Li, Dianze Chen, Huiqin Guo
  • Patent number: 11926676
    Abstract: Masked chimeric antigen receptor (CAR) constructs comprising an extracellular antigen binding domain specific tyrosine-protein kinase-like 7 (PTK7), which is linked to a mask peptide that blocks binding of masked CAR from binding to PTK7. Also provided herein are genetically engineered T cells expressing a masked CAR specific to PTK7 and therapeutic uses thereof.
    Type: Grant
    Filed: May 6, 2021
    Date of Patent: March 12, 2024
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Jason Sagert, Jui Dutta-Simmons, Jonathan Alexander Terrett
  • Patent number: 11926677
    Abstract: Presented herein are cancer peptide agents and uses thereof for treating cancer and/or inhibiting metastasis. Also presented herein are methods of treating cancer, or inhibiting metastasis of cancer in a subject, comprising administering a therapeutically effective amount of a composition comprising one or more cancer peptide agents to the subject. Also presented herein is a method of treating a cancer in a subject, or inhibiting metastasis of a cancer in a subject that comprises administering a therapeutically effective amount of a composition comprising one or more cancer peptide agents, and administering a chemotherapy or chemotherapeutic agent.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: March 12, 2024
    Assignee: SYMTHERA CANADA LTD.
    Inventor: Chai Ezerzer
  • Patent number: 11926678
    Abstract: Disclosed herein are composite polypeptide. According to various embodiments, the composite polypeptide includes a parent polypeptide and a metal binding motif capable of forming a complex with a metal cation. The composite polypeptide may be conjugated with a linker unit having a plurality of functional elements to form a multi-functional molecular construct. Alternatively, multiple composite polypeptides may be conjugated to a linker unit to form a molecular construct, or a polypeptide bundle. Linker units suitable for conjugating with the composite polypeptide having the metal binding motif are also disclosed.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: March 12, 2024
    Assignee: Immunwork Inc.
    Inventors: Tse-Wen Chang, Hsing-Mao Chu, Wei-Ting Tian, Yueh-Hsiang Yu
  • Patent number: 11926679
    Abstract: A modified peptide or a modified polypeptide has the amino acid sequence of Thr-Val-Asp-Ser-Cys-Leu-Thr (SEQ ID NO: 1) and adhesiveness to a norbornene-based polymer. A ratio of the total number of amino acids constituting the modified peptide or the modified polypeptide to the number of oligopeptides consisting of the amino acid sequence of SEQ ID NO: 1 contained in the modified peptide or the modified polypeptide is 7 or more and 80 or less. The number of oligopeptides consisting of the amino acid sequence of SEQ ID NO: 1 is 1.
    Type: Grant
    Filed: September 22, 2022
    Date of Patent: March 12, 2024
    Assignee: ZEON CORPORATION
    Inventor: Naoya Ichimura
  • Patent number: 11926680
    Abstract: This invention provides a method whereby Si microparticles (“Si MP”) with low cost and nitrogen-abundant chitin fibers from crustacean shells are used as raw materials to produce Si nanoparticles and nitrogen doped carbon composite via a scalable ball milling method. During the ball-milling process, Si MP are downsized, and the chitin fibers are wrapped around the particles. The milled product is then post-thermally treated to obtain Si and nitrogen doped carbon composites.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: March 12, 2024
    Assignee: University of Louisiana at Lafayette
    Inventor: Ling Fei
  • Patent number: 11926681
    Abstract: A curable composition capable of forming a cured product having a high refractive index and suppressed increase in reflectance, a cured product of the curable composition, and a method for producing the cured product using the curable composition. The curable composition includes a photopolymerizable monomer, metal oxide nanoparticles, and a photopolymerization initiating agent. The photopolymerizable monomer includes a compound represented by the following formula (a1).
    Type: Grant
    Filed: June 10, 2022
    Date of Patent: March 12, 2024
    Assignee: TOKYO OHKA KOGYO CO., LTD.
    Inventors: Hiroki Chisaka, Shinsuke Kawatsu
  • Patent number: 11926682
    Abstract: The present disclosure provides a method for preparing a polymerization initiator composition, including (a) a step of mixing water and a water-soluble initiator to prepare an aqueous initiator solution having a concentration of 1 to 10%; and (b) a step of activating the aqueous initiator solution, wherein the step of activating is performed by (b-1) a step of heat treating the aqueous initiator solution for 0.5 to 4.5 hours at a temperature of 48 to 62° C.; and (b-2) a step of treating the aqueous initiator solution to achieve pH of 1 to 7, where the steps above are performed in no particular order.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: March 12, 2024
    Assignee: LG CHEM LTD.
    Inventors: Heung Kwon Bae, Kyung Seog Youk, Jung Rae Lee, Hyun Min Lee, Joong Chul Lim, Min Jeong Kang
  • Patent number: 11926683
    Abstract: The present invention provides a thermosetting material, which contains the following components (A) to (C) and which, when measured with a rotational viscometer at a constant shear rate (JIS K7117-2:1999), exhibits a viscosity at 25° C. and 10 s?1 of 5 Pa·s or more and 200 Pa·s or less and, when measured with a rotational viscometer at a constant shear rate in the same manner as above, exhibits a viscosity at 25° C. and a shear rate of 100 s?1 of 0.3 Pa·s or more and 50 Pa·s or less. (A): a (meth) acrylate compound in which a substituted or unsubstituted alicyclic hydrocarbon group having 6 or more carbon atoms is ester-bonded, and which, when measured with a rotational viscometer at a constant shear rate in the same manner as above, exhibits a viscosity of 5 to 300 mPa·s as a viscosity measured at 25° C. and 10 to 100 s?1; (B): spherical silica; and (C): a black pigment.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: March 12, 2024
    Assignee: IDEMITSU KOSAN CO., LTD.
    Inventors: Yutaka Obata, Haruhiko Mori
  • Patent number: 11926684
    Abstract: A cast film inducing a bimodal ethylene-based polymer having a high density fraction (HDF) from 3.0% to 10.0%, an I10/I2 ratio from 5.5 to 7.0, a short chain branching distribution (SCBD) less than or equal to 10° C., a density from 0.910 g/cc to 0.920 g/cc, and a melt index (I2) from 1.0 g/10 mins to 8.0 g/10 mins.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: March 12, 2024
    Assignee: Dow Global Technologies LLC
    Inventors: Kyle E. Hart, Mehmet Demirors, Timothy W. Gambrel, Philip P. Fontaine, Vivek Kalihari, Hrishikesh R. Munj, Jon W. Hobson, Rajen M. Patel
  • Patent number: 11926685
    Abstract: Ethylene-based polymers of this disclosure include a melt viscosity ratio (V0.1/V100) at 190° C. of at least 10, where V0.1 is the viscosity of the ethylene-based polymer at 190° C. at a shear rate of 0.1 radians/second, and V100 is the viscosity of the ethylene-based polymer at 190° C. at a shear rate of 100 radians/second; and a molecular weight tail quantified by an MWD area metric, ATAIL, and ATAIL is less than or equal to 0.04 as determined by gel permeation chromatography using a triple detector.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: March 12, 2024
    Assignee: Dow Global Technologies LLC
    Inventors: Teresita Kashyap, Robert D. J. Froese, Daniel J. Arriola
  • Patent number: 11926686
    Abstract: Shape-programmable liquid crystal elastomers. The shape-programmable liquid crystal elastomers being synthesized by filling an alignment cell with liquid crystal monomers. The liquid crystal monomers align to a surface of the alignment cell and then are polymerized with a dithiol chain transfer agent. The alignment cell is configured to impose a director orientation on a portion of the shape-programmable liquid crystal elastomer. For some embodiments, liquid crystal elastomer laminates are prepared by arranging a plurality of liquid crystal elastomers such that a director orientation of each liquid crystal elastomer of the plurality is in registered alignment with an adjacent liquid crystal elastomer of the plurality. The arrangement is secured and the plurality of liquid crystal elastomers cured.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: March 12, 2024
    Assignee: United States of America as represented by the Secretary of the Air Force
    Inventors: Nicholas P Godman, Timothy J White, Hilmar Koerner, Benjamin A Kowalski, Anesia D Auguste, Tyler C Guin
  • Patent number: 11926687
    Abstract: A grafted polypropylene resin is prepared by a grafting reaction of a polar monomer capable of absorbing microwave so as to raise its temperature in a microwave field to more than 200° C. and a solid polypropylene resin using microwave irradiation without adding an initiator. The polar grafted polypropylene resin that does not contain initiator residues and does not have a significant reduction in molecular mass compared with a resin before grafting is obtained.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: March 12, 2024
    Assignees: CHINA PETROLEUM & CHEMICAL CORPORATION, BEIJING RESEARCH INSTITUTE OF CHEMICAL INDUSTRY, CHINA PETROLEUM & CHEMICAL CORPORATION
    Inventors: Jinliang Qiao, Songhe Wang, Xiaohong Zhang, Guicun Qi, Zhihai Song, Chuanlun Cai, Xiang Wang, Jinmei Lai, Binghai Li, Haibin Jiang, Yue Ru, Jiangru Zhang, Jianming Gao, Hongbin Zhang, Peng Han, Wenlu Liu